| Status: Excluded due to NICE appraisal | |
Meets AWMSG exclusion criteria due to NICE appraisal ID4067: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] |
|
Medicine details |
|
| Medicine name | isatuximab (Sarclisa®) |
| Formulation | 20mg/ml concentrate for solution for infusion |
| Reference number | 3539 |
| Indication | In combination with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults who have had at least 2 treatments (including lenalidomide and a proteasome inhibitor) and whose disease has progressed on the last treatment |
| Company | Sanofi |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/04/2020 |
| NICE guidance | |
| Commercial arrangement | None |
| Further information Commercial access agreement (CAA) terminates immediately for new patients as NICE negative (not recommended) |
|